Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
11.45
-0.02 (-0.17%)
Oct 1, 2026, 12:16 PM EDT - Market open
Climb Bio Market Cap
Climb Bio has a market cap or net worth of $657.65 million as of October 1, 2026. Its market cap has increased by 382.83% in one year.
Market Cap
657.65M
Enterprise Value
419.74M
1-Year Change
382.83%
Ranking
Category
Stock Price
$11.45
ChartMarket Cap Chart
Since August 10, 2021, Climb Bio's market cap has increased from $403.20M to $657.65M, an increase of 63.11%. That is a compound annual growth rate of 9.98%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 1, 2026 | 657.65M | 244.36% |
| Dec 31, 2025 | 190.98M | 57.83% |
| Dec 31, 2024 | 121.00M | 62.54% |
| Dec 29, 2023 | 74.45M | -23.65% |
| Dec 30, 2022 | 97.50M | -64.90% |
| Dec 31, 2021 | 277.76M | -31.11% |
| Aug 10, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| OmniAb | 689.88M |
| MiMedx Group | 679.97M |
| BlossomHill Therapeutics | 679.24M |
| DBV Technologies | 676.66M |
| Zevra Therapeutics | 673.41M |
| Nuvectis Pharma | 669.22M |
| Shattuck Labs | 656.38M |
| Silence Therapeutics | 649.06M |